Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$554M |
| 2 |
Apple
AAPL
|
+$513M |
| 3 |
Illumina
ILMN
|
+$360M |
| 4 |
argenx
ARGX
|
+$304M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$482M |
| 2 |
Sherwin-Williams
SHW
|
+$314M |
| 3 |
AbbVie
ABBV
|
+$310M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$244M |
| 5 |
Atlassian
TEAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.47% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
Nuvation Bio
NUVB
$2.26B
| $84.7K | ﹤0.01% |
51,497
+27,122
| +111% | +$55K |
|
2627
Inovio Pharmaceuticals
INO
$80.5M
| $83.7K | ﹤0.01% |
8,510
+5,000
| +142% | +$85.2K |
|
|
CNSL
2628
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $82.6K | ﹤0.01% |
31,962
+17,462
| +120% | +$62.6K |
|
2629
Future Fuel
FF
$280M
| $82.3K | ﹤0.01% |
+11,173
| New | +$96K |
|
|
LOGC
2630
DELISTED
ContextLogic
LOGC
| $78.1K | ﹤0.01% |
5,951
+3,717
| +166% | +$63.2K |
|
|
AGEN
2631
Agenus
AGEN
$296M
| $77.5K | ﹤0.01% |
2,590
+886
| +52% | +$37.4K |
|
2632
Rimini Street
RMNI
$454M
| $77.1K | ﹤0.01% |
+18,743
| New | +$84.4K |
|
|
CTEV
2633
Claritev Corp
CTEV
$579M
| $76.7K | ﹤0.01% |
1,826
+1,111
| +155% | +$50.2K |
|
2634
Aurora
AUR
$13.6B
| $76.1K | ﹤0.01% |
+54,775
| New | +$81K |
|
2635
Microvast
MVST
$280M
| $74.6K | ﹤0.01% |
59,925
+30,985
| +107% | +$45K |
|
|
KLRS
2636
Kalaris Therapeutics
KLRS
$96.1M
| $74.3K | ﹤0.01% |
+821
| New | +$105K |
|
|
KZR
2637
DELISTED
Kezar Life Sciences
KZR
| $73.6K | ﹤0.01% |
2,356
+1,232
| +110% | +$71.3K |
|
2638
Lexicon Pharmaceuticals
LXRX
$1.04B
| $69.4K | ﹤0.01% |
28,630
+17,269
| +152% | +$39.6K |
|
2639
Purple Innovation
PRPL
$31.3M
| $67.6K | ﹤0.01% |
1,030
+560
| +119% | +$62.5K |
|
2640
Heron Therapeutics
HRTX
$60.6M
| $67.5K | ﹤0.01% |
44,526
+26,787
| +151% | +$67.1K |
|
2641
Angi Inc
ANGI
$185M
| $67.3K | ﹤0.01% |
2,971
+1,663
| +127% | +$42.6K |
|
2642
Bridger Aerospace
BAER
$70.6M
| $67.2K | ﹤0.01% |
+14,772
| New | +$85.5K |
|
2643
Amneal Pharmaceuticals
AMRX
$5.5B
| $62.6K | ﹤0.01% |
44,720
+24,979
| +127% | +$49.7K |
|
|
BHIL
2644
DELISTED
Benson Hill, Inc.
BHIL
| $62.6K | ﹤0.01% |
1,575
+800
| +103% | +$59.7K |
|
|
WE
2645
DELISTED
WeWork Inc.
WE
| $62.2K | ﹤0.01% |
2,018
+1,036
| +105% | +$56.6K |
|
2646
Adicet Bio
ACET
$76.6M
| $61.2K | ﹤0.01% |
+665
| New | +$83.5K |
|
2647
Energy Vault
NRGV
$645M
| $60.1K | ﹤0.01% |
28,128
+16,523
| +142% | +$56.3K |
|
|
CMAX
2648
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $59.2K | ﹤0.01% |
741
+361
| +95% | +$42.2K |
|
2649
Seer Inc
SEER
$119M
| $58.9K | ﹤0.01% |
+15,299
| New | +$70.4K |
|
2650
Nektar Therapeutics
NKTR
$2.52B
| $57.8K | ﹤0.01% |
5,507
+3,075
| +126% | +$93K |
|
Similar funds
Janus Henderson Group's Q1 2023 Portfolio in Review
As of Q1 2023, Janus Henderson Group held 2,845 positions worth $152B, up 8.3% from $140B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Janus Henderson Group's Q1 2023 filing shows 389 new, 1,670 increased, 578 reduced and 160 closed positions. Its largest new stake was GE HealthCare: 882,749 shares worth $72.4M. The largest sale was Meta Platforms (Facebook), an estimated $482M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2023 buy was GE HealthCare: 882,749 shares worth $72.4M.
- Janus Henderson Group added most to Linde in Q1 2023, an estimated $554M increase.
- Janus Henderson Group's biggest Q1 2023 reduction was Meta Platforms (Facebook), cutting an estimated $482M.
- Janus Henderson Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $31.7M.
- Janus Henderson Group's ten largest holdings make up 24% of its $152B portfolio in Q1 2023.
- Janus Henderson Group opened 389 new positions and closed 160 in Q1 2023.
- Janus Henderson Group's portfolio value rose 8.3% quarter-over-quarter to $152B.
Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.